S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
NASDAQ:TXMD

TherapeuticsMD (TXMD) Stock Price, News & Analysis

$2.28
+0.03 (+1.33%)
(As of 03:15 PM ET)
Today's Range
$2.25
$2.31
50-Day Range
$2.23
$2.69
52-Week Range
$1.95
$4.72
Volume
8,657 shs
Average Volume
18,587 shs
Market Capitalization
$24.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TXMD stock logo

About TherapeuticsMD Stock (NASDAQ:TXMD)

TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TXMD Stock Price History

TXMD Stock News Headlines

TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
TherapeuticsMD Inc TXMD
TherapeuticsMD to Consider Strategic Alternatives
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
See More Headlines
Receive TXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
3/28/2024
Next Earnings (Estimated)
4/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TXMD
Previous Symbol
NYSEMKT:TXMD
Employees
1
Year Founded
N/A

Profitability

Net Income
$112 million
Pretax Margin
60.97%

Debt

Sales & Book Value

Annual Sales
$69.96 million
Book Value
$3.73 per share

Miscellaneous

Free Float
10,453,000
Market Cap
$23.81 million
Optionable
Optionable
Beta
1.03
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

TXMD Stock Analysis - Frequently Asked Questions

Should I buy or sell TherapeuticsMD stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares.
View TXMD analyst ratings
or view top-rated stocks.

How have TXMD shares performed in 2024?

TherapeuticsMD's stock was trading at $2.25 at the beginning of the year. Since then, TXMD stock has increased by 1.3% and is now trading at $2.28.
View the best growth stocks for 2024 here
.

When is TherapeuticsMD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 5th 2024.
View our TXMD earnings forecast
.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) released its earnings results on Monday, August, 14th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.17. The business had revenue of $0.44 million for the quarter. TherapeuticsMD had a trailing twelve-month return on equity of 133.83% and a net margin of 47.29%.

When did TherapeuticsMD's stock split?

Shares of TherapeuticsMD reverse split before market open on Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a variety of institutional and retail investors. Top institutional investors include ADAR1 Capital Management LLC (2.57%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Bernick, Cooper C Collins, Edward Borkowski, Gail K Naughton, James Darecca, Marlan D Walker, Marlan D Walker, Michael C Donegan, Michael C Donegan, Paul Bisaro, Robert G Finizio, Rubric Capital Management Lp, Tommy G Thompson and Tommy G Thompson.
View institutional ownership trends
.

How do I buy shares of TherapeuticsMD?

Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TXMD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners